Welcome!

News Feed Item

Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Insmed Incorporated Analyst Notes

On February 19, 2014, Insmed Incorporated (Insmed) provided an interim update from its CLEAR-110 study-- an ongoing life-threatening, open-label extension study of once-daily ARIKACE® to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. The Company informed that the data showed patients taking ARIKACE actually saw their FEV (Forced Expiratory Volume) levels remain above baseline on average, and also experienced a sustained reduction in density of Pa sputum while on treatment. Commenting on the study results, Will Lewis, President and CEO of Insmed, stated, "With the results achieved in our Phase 3 trial, along with these positive interim data, we continue our preparation for regulatory filings with the European Medicines Agency and Health Canada, which remain on target for mid-year." The full analyst notes on Insmed Incorporated are available to download free of charge at:

http://www.AnalystsReview.com/03062014/INSM/report.pdf

--

Medtronic, Inc. Analyst Notes

On February 26, 2014, Medtronic, Inc.'s (Medtronic) stock went up by 0.63%, closing at $57.81. After opening at $57.63, the stock oscillated in a range of $57.52-$58.22, with total volume of 4.00 million. For the past three day trading period, Medtronic shares went up by 1.21%, compared to the Dow Jones Industrial Average which gained 0.59% during the same period. The full analyst notes on Medtronic, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/MDT/report.pdf

--

CR Bard Inc. Analyst Notes

On February 26, 2014, CR Bard Inc.'s (CR Bard) stock went up by 0.76%, ending the day at $143.04. The stock opened at $142.04, and traded in a range of $141.68-$144.06 during the session. Over the past three day trading period, the Company's stock went up by 1.04%, compared to the S&P 500 which advanced 0.49% during the same period. The full analyst notes on CR Bard Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/BCR/report.pdf

--

Laboratory Corp. of America Holdings Analyst Notes

On February 24, 2014, Laboratory Corp. of America Holdings (LabCorp) announced that an agreement has been entered into with Thermo Fisher Scientific, Inc (Thermo Fisher), under which the Company gets access to latter's Thermo Scientific ImmunoCAP™ allergy testing portfolio of more than 600 allergens and 100 allergen components. Commenting on the agreement, Dr. Mark Brecher, LabCorp's Chief Medical Officer, stated, "LabCorp offers an extensive test menu which supports a diagnosis of allergy and, just as importantly, can assist in ruling out allergies as a source of symptoms and thereby suggest other etiologies. We will continue to offer a comprehensive range of tests for regional allergies, food allergies, oral allergy syndrome, pediatric allergens and workplace allergy exposures, and we will develop customized panels to improve treatment practices and enhance patient outcomes." The full analyst notes on Laboratory Corp. of America Holdings are available to download free of charge at:

http://www.AnalystsReview.com/03062014/LH/report.pdf

--

Acceleron Pharma, Inc. Analyst Notes

On February 26, 2014, Acceleron Pharma, Inc. (Acceleron) reported its Q4 2013 and full year 2013 financial results. Collaboration revenue of Acceleron went up to $11.5 million in the quarter and to $57.2 million in full year 2013, compared to $4.0 million in Q4 2012 and $15.3 million in full year 2012.

For the quarter, net loss applicable to common shareholders was $18.1 million, or $0.64 per diluted share, compared to net loss applicable to common shareholders of $17.1 million, or $7.10 per diluted share, in Q4 2012. Full year 2013 net loss applicable to common shareholders was $39.0 million, or $4.15 per diluted share, compared to net loss applicable to common shareholders of $59.6 million, or $24.84 per diluted share, in full year 2012. Acceleron stated that Q4 2013 and full year 2013 results were affected by the expenses associated with marking to market outstanding warrants to purchase of common stock. The full analyst notes on Acceleron Pharma, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/XLRN/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--


=============

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com 

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...